And don't all groan because,

[Guest guest]

I think that FINALLY....here is some good news for us.

http://www.nature.com/cgi-taf/DynaPage.taf?file=/nrc/journal/v2/n2/full/nrc725_fs.html

If you are up on your understanding of the key players in NF2, I think you will agree that this article gives us great ammunition to ask where is the research into this pathway of intervention....

In my limited understanding (am not being coy, am only vigilant in literature surveillance, and I even hate how sanctimonious I probably sound, not true of course), this is OUR pathway of drug intervention AND this article shows how many other, more lucrative, cancers/diseases they could target and nab along the way (also explains some of those crossovers, but that is another story).

Taken from the most recent Nature Cancer, it points out that the RHO family is potentially a viable pathway of intervention for many cancers (if you persist through article NF2 does get a mention), which has been BLEEDINGLY obvious from NF2 for quite some time. However, this article gives me hope that there is some very real routes to be taken using the Rho family, something I always assumed, in ignorance, must be in the too hard basket, because no-one is doing it, as far as I know. Anybody know any different? Please tell me. I think once I ran it past Sugen, and got a polite negative.

I don't pretend to understand it all, but I know enough to recognise if some group did take up this challenge, we would SURELY benefit. Not just some apoptic or angiogenesis drug developed for some other cancer, but a drug that is designed to target the nf2 tumorigenesis route, so potentially a drug with our name all over it....

As some of you keep saying, the squeaky wheel gets fixed, where there is a will there is a way. etc. etc. and a I am sure could tell you the story of how aptosyn was developed ( a father got the drug developed to save his son the ravages of FAPS.... his lead came from someone who had FAPS and was using an anti-inflammatory drug for his arthritis (or some such thing) and coincidentally found that his colonic polyps disappeared... sorry, very abridged version).

ANYWAY, now that we have an article published in a reputable source, supporting this pathway of intervention, even suggesting how viable it is as an option, let's start asking NF bodies/ biotechs/ researchers, to develop something/ work on it for us.

Or are they already? Feedback please before I start doing the rounds.

Have not had a digest for a while but I fear I must have taken up half of it.

[Guest guest]

Rosemary, I halfway believe that when there is a drug developed to help us it

will probably be named afteryou. You are more knowledgabe than 99% of us and I

thank you for taking a proactive stance on nf2, for thesake of us all,

pleasecontinue.

(one of the drawbacks of digest is long messages, its a choice, so people don't

have to use digest mode, I think id go nuts if I had to wade through it. mail

filters is theway to go.)

cindy

> I think that FINALLY....here is some good news for us.

>

> http://www.nature.com/cgi-taf/DynaPage.taf?file=/nrc/journal/v2/n2/full/nrc7

> 25_fs.html

>

> If you are up on your understanding of the key players in NF2, I think you

> will agree that this article gives us great ammunition to ask where is the

> research into this pathway of intervention....

>

> In my limited understanding (am not being coy, am only vigilant in

> literature surveillance, and I even hate how sanctimonious I probably sound,

> not true of course), this is OUR pathway of drug intervention AND this

> article shows how many other, more lucrative, cancers/diseases they could

> target and nab along the way (also explains some of those crossovers, but

> that is another story).

>

> Taken from the most recent Nature Cancer, it points out that the RHO family

> is potentially a viable pathway of intervention for many cancers (if you

> persist through article NF2 does get a mention), which has been BLEEDINGLY

> obvious from NF2 for quite some time. However, this article gives me hope

> that there is some very real routes to be taken using the Rho family,

> something I always assumed, in ignorance, must be in the too hard basket,

> because no-one is doing it, as far as I know. Anybody know any different?

> Please tell me. I think once I ran it past Sugen, and got a polite negative.

>

> I don't pretend to understand it all, but I know enough to recognise if some

> group did take up this challenge, we would SURELY benefit. Not just some

> apoptic or angiogenesis drug developed for some other cancer, but a drug

> that is designed to target the nf2 tumorigenesis route, so potentially a

> drug with our name all over it....

>

> As some of you keep saying, the squeaky wheel gets fixed, where there is a

> will there is a way. etc. etc. and a I am sure could tell you the

> story of how aptosyn was developed ( a father got the drug developed to save

> his son the ravages of FAPS.... his lead came from someone who had FAPS and

> was using an anti-inflammatory drug for his arthritis (or some such thing)

> and coincidentally found that his colonic polyps disappeared... sorry,

> very abridged version).

>

> ANYWAY, now that we have an article published in a reputable source,

> supporting this pathway of intervention, even suggesting how viable it is

> as an option, let's start asking NF bodies/ biotechs/ researchers, to

> develop something/ work on it for us.

>

> Or are they already? Feedback please before I start doing the rounds.

>

> Have not had a digest for a while but I fear I must have taken up half of

> it.

>

[Guest guest]

Rosemary

Congratulations once again, you never cease to amaze with your in-depth research.

Thankyou from me

ine

And don't all groan because,

I think that FINALLY....here is some good news for us.http://www.nature.com/cgi-taf/DynaPage.taf?file=/nrc/journal/v2/n2/full/nrc725_fs.htmlIf you are up on your understanding of the key players in NF2,